- Home
- ALT vs ALLO Comparison
ALT vs ALLO Comparison
Compare ALT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- ALLO
- Stock Information
- Founded
- ALT 1997
- ALLO 2017
- Country
- ALT United States
- ALLO United States
- Employees
- ALT N/A
- ALLO N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALT Health Care
- ALLO Health Care
- Exchange
- ALT Nasdaq
- ALLO Nasdaq
- Market Cap
- ALT 457.0M
- ALLO 431.9M
- IPO Year
- ALT N/A
- ALLO 2018
- Fundamental
- Price
- ALT $8.25
- ALLO $1.87
- Analyst Decision
- ALT Buy
- ALLO Buy
- Analyst Count
- ALT 7
- ALLO 12
- Target Price
- ALT $20.00
- ALLO $10.06
- AVG Volume (30 Days)
- ALT 3.4M
- ALLO 2.7M
- Earning Date
- ALT 11-12-2024
- ALLO 11-07-2024
- Dividend Yield
- ALT N/A
- ALLO N/A
- EPS Growth
- ALT N/A
- ALLO N/A
- EPS
- ALT N/A
- ALLO N/A
- Revenue
- ALT $52,000.00
- ALLO $43,000.00
- Revenue This Year
- ALT N/A
- ALLO N/A
- Revenue Next Year
- ALT N/A
- ALLO N/A
- P/E Ratio
- ALT N/A
- ALLO N/A
- Revenue Growth
- ALT N/A
- ALLO 26.47
- 52 Week Low
- ALT $5.28
- ALLO $1.78
- 52 Week High
- ALT $14.84
- ALLO $5.78
- Technical
- Relative Strength Index (RSI)
- ALT 48.05
- ALLO 36.24
- Support Level
- ALT $7.71
- ALLO $1.83
- Resistance Level
- ALT $9.59
- ALLO $2.12
- Average True Range (ATR)
- ALT 0.81
- ALLO 0.16
- MACD
- ALT -0.17
- ALLO -0.02
- Stochastic Oscillator
- ALT 17.17
- ALLO 12.16
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.